CERO THERAPEUTICS HOLDINGS, INC. (CEROW) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-01

Key Insights

CERO secured a $400,000 convertible note with $500,000 principal value from Keystone Capital Partners, with an option to borrow up to $1,000,000 total, indicating potential funding needs and dilution risk for existing shareholders through conversion.
The conversion price is set at the lesser of $0.05 or 80% of the 20-day average low trading price, which creates significant dilution risk if the stock trades below $0.0625, and the 4.99% beneficial ownership limitation may not fully protect against substantial share issuance.
The company must file a registration statement (Form S-1 or S-3) to enable resale of conversion shares, which will publicly disclose substantial dilution and may pressure the stock price upon effective registration.
The 10% annual interest rate and April 2027 maturity date represent relatively expensive debt financing, suggesting limited access to traditional capital markets and potential financial stress for an early-stage biotech company.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-14

CERO Therapeutics has secured a $1 million convertible note financing from Keystone Capital Partners, providing additional capital to fund its operations.
The convertible note has favorable terms for CERO, with a low conversion price and a long maturity date, potentially allowing the company to raise capital at advantageous prices.
The company must file a registration statement to register the resale of the shares underlying the convertible note, which will increase transparency and liquidity for investors.

Filed: 2026-03-11

Cero Therapeutics Holdings, Inc. issued a $937,500 convertible promissory note to Keystone Capital Partners, LLC, providing additional financing of up to $1 million.
The note is convertible into common stock at a 20% discount to the average of the 5 lowest trading prices in the prior 20 days, which could lead to significant dilution for existing shareholders.
The company is required to file a registration statement to cover the resale of the shares issuable upon conversion of the note, providing liquidity for the lender.

Filed: 2026-02-13

Cero Therapeutics Holdings, Inc. has issued a convertible promissory note to Keystone Capital Partners, LLC for up to $1 million, providing additional financing for the company's operations.
The convertible note has a 10% annual interest rate, matures in July 2027, and is convertible into the company's common stock at a discounted price.
The company has dismissed its independent auditor, Wolf & Company, P.C., due to a previously disclosed material weakness in internal controls, which could raise concerns about the company's financial reporting.

Filed: 2026-02-04

Cero Therapeutics Holdings, Inc. is an emerging growth company in the biotechnology industry, focusing on transplantation and cellular therapy research.
The company is presenting a poster at an industry conference, which provides a summary of its ongoing R&D efforts and pipeline.
Investors should review the company's SEC filings and public announcements for more detailed and up-to-date information on its business and financial performance.

Filed: 2026-02-03

CERO Therapeutics Holdings, Inc. has been delisted from the Nasdaq Stock Market after appealing the decision, which could negatively impact the company's visibility and access to capital markets.
The company's securities are no longer traded on a major exchange, which may limit investor interest and trading liquidity.
The delisting event could signal broader challenges for the company, and investors should closely monitor any further developments or strategic actions taken by the management team.

Filed: 2026-01-07

Cero Therapeutics is an emerging growth company developing novel treatments for acute myeloid leukemia (AML) and other hematological malignancies.
The company has provided a clinical update on its Phase 1 trial of CER-1236 in AML, highlighting key safety data and a platelet transfusion-free interval observed in a patient with myelodysplastic syndrome/AML.
The company plans to use the presentation provided in the filing for meetings with investors, analysts and others to discuss its progress and development plans.

Other reports for CERO THERAPEUTICS HOLDINGS, INC.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.